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The Contursi Family 20 Years
Later: Intrafamilial Phenotypic
Variability of the SNCA
p.A53T Mutation
The SNCA/alpha-synuclein p.A53T mutation segregating
in the Contursi kindred was the first mutation ever described
in inherited Parkinson’s disease (PD).1,2 We directly exam-
ined 10 subjects (4 PD patients and 6 asymptomatic rela-
tives) of a branch of the Contursi kindred. We also collected
data on 11 members affected by history, through interviews
and inspection of available medical records. Nine had died
in the fourth to seventh decade diagnosed with PD (plus
psychiatric features in 3), whereas 2 were reported to have
severe psychiatric disturbances and were unavailable for
examination.
After obtaining ethics approval and written informed con-
sent, all subjects underwent a complete neurological exami-
nation (see Video 1) and SNCA p.A53T mutation testing.
The 4 PD patients (age, 426 9.8 years), and 2 unaffected
individuals (age, 29.56 2.1 years) resulted as heterozygous
for the mutation. Two affected (III:1, IV:1) and 2 unaffected
(IV:2, IV:6) carriers also underwent extensive neuropsycho-
logical and psychiatric assessment, olfaction evaluation, and
dopamine transporter imaging with single-photon emission
computed tomography (DAT-SPECT); 3T brain MRI was
performed in 3 subjects (III:1, IV:2, and IV:6; Fig. 1).
Although the overall phenotype in the 4 patients was typical
of SNCA-related PD with early, asymmetric onset, initial good
response to dopaminergic therapy and early motor complica-
tions,3 a relevant variability was observed in the combination
and severity of motor symptoms (partially responding to levo-
dopa and DBS in III-9) and nonmotor features (Table 1). Age
at onset varied from 26 to 48 years (mean, 32.76 10.5), with
longer disease duration than previously reported (from 2 to 19
years; mean, 9.26 8.5). Cognitive deficits were present in all 4
patients, ranging from frank dementia in those with longer dis-
ease duration (III-8, III-9) to moderate cognitive impairment
(III-1) or slight isolated executive dysfunction (IV-1) in those
with a shorter one. Depression and anxiety were detected in 3
patients, behavioral disorders in 2, and dysautonomia in 2.
Olfaction was impaired in both tested patients. Although the
variable severity could depend on the different disease dura-
tion, the wide range of ages at onset among carriers of the
same genetic mutation remains unexplained, suggesting the
existence of yet unknown environmental, genetic, and/or epige-
netic modifiers.4
Interestingly, 2 asymptomatic carriers, ages 31 and 28
years, were clinically unaffected. Their general cognitive
functions were normal and they did not refer any sleep or
mood disorder. However, the younger one (IV:2) presented
an objective olfactory deficit and an abnormal DAT scan,
suggesting an underlying, still subclinical, neurodegenerative
process. The existence of SNCA mutation carriers who
remain clinically asymptomatic at ages beyond the expected
age of onset has been reported, implying reduced pene-
trance.5 However, our carriers were still younger than the
latest age of onset in the family; therefore, any conclusion
would be merely speculative and further clinical follow-up is
necessary.
In conclusion, our data further highlight the relevant
intrafamilial phenotypic variability in carriers of the SNCA
p.A53T mutation, suggesting a role for yet unknown genetic
or environmental modifiers. Follow-up studies are encouraged
to better define the clinical spectrum of PD caused by SNCA
gene mutations.
Lucia Ricciardi, MD, PhD,1 Simona Petrucci, MD,2,3
Daniela Di Giuda, MD,4 Laura Serra, PhD,5
Barbara Spano, MD, PhD,5 Mariachiara Sensi, MD,6
Monia Ginevrino, BSc,3 Fabrizio Cocciolillo, MD,4
Marco Bozzali, MD, PhD,5 Enza Maria Valente, MD, PhD,3,7
and Alfonso Fasano, MD, PhD8,*
1Sobell Department of Motor Neuroscience and Movement
Disorders, Institute of Neurology, University College
London, London, United Kingdom; 2Department of
Neurology and Psychiatry, “Sapienza” University of Rome,
Rome, Italy; 3IRCCS Casa Sollievo della Sofferenza,
CSS-Mendel Institute and San Giovanni Rotondo, Rome,
Italy; 4Institute of Nuclear Medicine, Universita Cattolica
del Sacro Cuore, A. Gemelli University Hospital, Rome,
Italy; 5Neuroimaging Laboratory, IRCCS Santa Lucia
Foundation, Rome, Italy; 6Department of
Neuroscience-Rehabilitation, S. Anna University-Hospital
of Ferrara, Ferrara, Italy; 7Department of Medicine and
Surgery, University of Salerno, Salerno, Italy; 8Morton and
Gloria Shulman Movement Disorders Center and the
Edmond J. Safra Program in Parkinson’s Disease, Toronto
Western Hospital, University Health Network, Toronto,
Ontario, Canada
------------------------------------------------------------
*Correspondence to: Dr. Alfonso Fasano, University of Toronto
Movement Disorders Center, Toronto Western Hospital, 399 Bathurst
Street, 7 Mc412, Toronto, ON, Canada M5T 2S8;
E-mail: alfonso.fasano@uhn.ca or alfonso.fasano@gmail.com
Funding agencies: This work was partly supported from the Italian
Ministry of Health (Ricerca Corrente 2015) and the European Community
(FP7–MeFoPa grant).
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online
version of this article.
Received: 18 July 2015; Revised: 25 November 2015; Accepted: 6
December 2015
Published online 22 January 2016 in Wiley Online Library
(wileyonlinelibrary.com). DOI: 10.1002/mds.26549
L E T T E R S : N E W O B S E R V A T I O N S
Movement Disorders, Vol. 31, No. 2, 2016 257
References
1. Golbe LI, Di Iorio G, Sanges G, et al. Clinical genetic analysis of
Parkinson’s disease in the Contursi kindred. Ann Neurol 1996;40:
767-775.
2. Polymeropoulos M, Lavedan C, Leroy E et al. Mutation in the
alpha-synuclein gene identified in families with Parkinson’s disease.
Science 1997;276:2045-2047.
3. Kasten M, Klein C. The many faces of alpha-synuclein mutations.
Mov Disord 2013;28:697-701.
4. Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C,
Kehrer-Sawatzki H. Where genotype is not predictive of phenotype:
towards an understanding of the molecular basis of reduced pene-
trance in human inherited disease. Hum Genet 2013;132:1077-
1130.
5. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano
M, Anastasopoulos I. Mutated a-synuclein gene in two Greek
kindreds with familial PD: incomplete penetrance? Neurology 1999;
52:651.
Supporting Data
Additional Supporting Information may be found in the
online version of this article
FIG. 1. (A) Simplified pedigree of the family. Black symbols denote affected individuals with both PD and psychiatric disease; gray symbols denote
patients with PD; white and gray striped symbols denote patients with psychiatric disease only. A thin horizontal line above symbols denotes clinically
and genetically examined individuals. Dead members are marked with a diagonal bar. The arrow indicates the proband. –5no SNCA muta-
tion;15 heterozygous for SNCA p.A53T mutation. (B) Transaxial 123I-FP-CIT SPECTslices (1 pixel thick) at the level of the striatum SPECTwas abnormal
in 2 patients and 1 healthy carrier and normal in subject IV:6. Patients III-1 and IV-1 showed decreased radiotracer uptake bilaterally in the striatum. The
asymptomatic carrier, IV-2, also showed a reduction in 123I-FP-CIT uptake in the right putamen. Activity was intense in the caudate nuclei and putamina
of subject IV-6 (Supporting Table 1). (C) Illustrated here are some images obtained from patients’ MR scanning. T1-weighted images (left side) did not
reveal any sign suggestive for regional brain atrophy. Fluid-attenuated inversion recovery scans did not show any remarkable macroscopic abnormalities
in patients’ white matter. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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